Menu
Montecito
PacPremier
Loading...
You are here:  Home  >  'Repatha'  -  Page 4
Latest

Amgen shares climb after judge upholds Repatha patents

By   /  Friday, January 6th, 2017  /  Central Coast Health Watch, Latest news, Law  /  Comments Off on Amgen shares climb after judge upholds Repatha patents

A ruling in a patent law case regarding a new anti-cholesterol drug involving Thousand Oaks biotech giant Amgen has skyrocketed Amgen shares. Amgen filed a patent infringement lawsuit against Sanofi and Regeneron in the U.S. District Court of Delaware in October 2014 to block the development and sale of the drug Praluent, which was developed Read More →

Read More →
Latest

Amgen leukemia drug cures 39 percent of treated patients, study finds

By   /  Tuesday, October 4th, 2016  /  Central Coast Health Watch, Latest news  /  Comments Off on Amgen leukemia drug cures 39 percent of treated patients, study finds

Amgen’s new leukemia drug cured 39 percent of pediatric patients who received treatment, the Thousand Oaks company said Oct. 3 after publishing results of a new study in the Journal of Clinical Oncology. Blincyto, which treats a rare form of the disease known as precursor B-cell acute lymphoblastic leukemia, sent 27 patients out of 70 Read More →

Read More →
Latest

FDA OKs wearable injector for Amgen’s Repatha cholesterol drug

By   /  Monday, July 11th, 2016  /  Central Coast Health Watch, Latest news  /  Comments Off on FDA OKs wearable injector for Amgen’s Repatha cholesterol drug

The U.S. Food and Drug Administration approved a new type of injector for Amgen’s cholesterol reducing drug Repatha on July 11. The FDA approved a wearable injector, called the “Pushtronex” system, that sticks to patients’ bodies and delivers a dose of the drug monthly under the skin. Patients can perform moderate physical activities like walking Read More →

Read More →
Latest

Amgen exceeds Wall Street expectations for first quarter earnings

By   /  Thursday, April 28th, 2016  /  Central Coast Health Watch, Earnings, Latest news, Tri-County Public Companies  /  Comments Off on Amgen exceeds Wall Street expectations for first quarter earnings

Amgen blew away Wall Street expectations and raised its 2016 guidance when it released first quarter earnings April 28. The Thousand Oaks biotech giant had profits of $2.2 billion, up from $1.91 billion during the same quarter last year. Revenues of $5.53 billion were also up from $5 billion in 2015 and surpassed analyst estimates Read More →

Read More →
Latest

Amgen wins lawsuit against Regeneron, Sanofi for violating patents

By   /  Wednesday, March 16th, 2016  /  East Ventura County, Latest news, Law  /  Comments Off on Amgen wins lawsuit against Regeneron, Sanofi for violating patents

A federal jury decided in favor of Amgen on March 16 in a lawsuit filed against Regeneron Pharmaceuticals and Sanofi for violating patents on a cholesterol reducing drug. In October 2014, Thousand Oaks-based Amgen sued Paris-based Sanofi and Tarrytown, N.Y.-based Regeneron for violating patents on its cholesterol reducing drug Repatha. Sanofi and Regeneron co-developed Praluent Read More →

Read More →
Latest

Amgen buys biotech company, partners with another

By   /  Wednesday, September 16th, 2015  /  Central Coast Health Watch, Latest news, Technology, Top Stories, Tri-County Public Companies  /  Comments Off on Amgen buys biotech company, partners with another

Thousand Oaks-based biopharmaceutical giant Amgen bought a Netherlands-based company and partnered with a Monrovia-based company in an effort to fend off competitors. Amgen announced Sept. 16 that it will buy Dezima, a biotech company focused on developing new treatments for dyslipidemia, a disease where a person has an abnormal amount of lipids in their blood. Read More →

Read More →
Latest

Amgen’s cholesterol-lowering drug Repatha gets U.S. approval

By   /  Thursday, August 27th, 2015  /  Latest news, Tri-County Public Companies  /  Comments Off on Amgen’s cholesterol-lowering drug Repatha gets U.S. approval

Thousand Oaks-based biotech giant Amgen won U.S. approval for its powerful cholesterol-lowering drug Repatha for certain patients, making it the second in a new class of treatments to come to market, Bloomberg News reported Aug. 27. The Food and Drug Administration cleared Repatha for people with hard-to-treat levels of bad cholesterol, according to a statement Read More →

Read More →